Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
Friend’s Advice Causes Patient Problems
TOP STORIES — Diabetes News and Research
People with Type 1 Diabetes Test Freestyle Libre Flash System Performance
EXCEED Trial: Efpeglenatide Displays Significant Reduction in HbA1c and Body Weight
Preventing Diabetes with Resistance Training or Aerobic Exercise
MOST POPULAR ARTICLES OF THE MONTH
#1 Updated Consensus Report on Diabetic Nutrition Therapy
#2 What Causes Blood Glucose to Go Down or Up During Exercise
Editor's Note
Our former intern, Amber Satz, PharmD Candidate, LECOM School of Pharmacy, was reviewing some info on GLP-1 Analogs and came across a new entry into the class.
Efpeglenatide is a new weekly analog from Sanofi. It appears to be as effective as all other weekly’s out there, and it will be interesting to see what the delivery device looks like and how they will price it to compete in a crowded market. Check what Amber learned in her research by clicking here.
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
Last week I saw a patient who seemed to be losing control of her blood glucose levels. She had been doing well and her A1c had been around 6.0 – 6.3 for the past couple of years. She was doing this while only on metformin 1000 twice a day. She was referred to me by her physician because of high after-meal readings ranging up to 350 mg/dl. I went over her medical history and medications looking for a possible problem and found nothing.
TOP STORIES — Diabetes News and Research
Can the Freestyle Libre Flash glucose monitoring system perform accurately when challenged?
Efpeglenatide, a new GLP-1 receptor agonist, referenced to liraglutide in Phase II trial.
Can resistance training improve beta-cell function in patients with prediabetes?
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.